Skip to main content

Advertisement

Table 1 Calcium related genes suspects to human prostatic tumorigenesis

From: Calcium and CaSR/IP3R in prostate cancer development

Genes Cases_Altered % (cases) Sources of data bases
TCGA Provisional 498 patients/499 samples TCGA cell 2015 333 patients/333 samples NEPC 2016 81 patients/114 samples FHCRC, 2016 63 patients/176 samples MICH 59 patients/61 samples SU2C 150 patients/150 samples
PTEN Mutation 1.2% (6) 1.5% (5) 0.88% (1) 1.7% (3) 8.2% (5) 7.33% (11)
Amplification 0 0 7.02% (8) 0 0 0
Deep deletion 4.21% (21) 4.5% (15) 14.91% (17) 7.95% (14) 39.34% (24) 26% (39)
mRNA/protein ↓ 8.01% (40) 9.01% (30) 0 18.18% (32) 0 2% (3)
Multiple alteration 16.23% (81) 11.41% (38) 0.88% (1) 23.3% (41) 1.64% (1) 6.66% (10)
Patients_Altered 30% (147) 26% (88) 30% (24) 63% (40) 51% (30) 42% (63)
RYR1 RYR2 RYR3 Mutation 6.61% (33) 3.9% (13) 7.02% (8) 9.09% (16) 14.75% (9) 15.33% (23)
Amplification 1.4% (7) 1.5% (5) 27.19% (31) 3.41% (6) 1.64% (1) 1.33% (2)
Deep deletion 3.61% (18) 3.9% (13) 0.88% (1) 1.14% (2) 0 1.33% (2)
mRNA/protein ↓ 7.62% (38) 8.11% (27) 0 14.2% (25) 0 6% (9)
Multiple alteration 2% (10) 0.6% (2) 3.51% (4) 1.7% (3) 3.28% (2) 0.67% (1)
Patients_Altered 21% (106) 18% (60) 44% (36) 43% (27) 20% (12) 25% (37)
RYR1 RYR2 RYR3 FKBP1A FKBP1B Mutation 6.01% (30) 3.6% (12) 7.02% (8) 6.82% (12) 14.75% (9) 14.67% (22)
Amplification 1.4% (7) 1.8% (6) 28.95% (33) 3.41% (6) 1.64% (1) 1.33% (2)
Deep deletion 4.21% (21) 4.2% (14) 0.88% (1) 1.14% (2) 1.64% (1) 1.33% (2)
mRNA/protein ↓ 14.83% (74) 13.21% (44) 0 21.02% (37) 0 8% (12)
Multiple alteration 3.01% (15) 1.2% (4) 3.51% (4) 5.11% (9) 3.28% (2) 1.33% (2)
Patients_Altered 30% (147) 24% (80) 47% (38) 52% (33) 22% (13) 27% (40)
IP3R1 IP3R2 IP3R3 Mutation 2.81% (14) 1.8% (6) 3.51% (4) 3.98% (7) 4.92% (3) 2.67% (4)
Amplification 0.4% (2) 0.3% (1) 26.32% (30) 5.68% (10) 1.64% (1) 3.33% (5)
Deep deletion 2% (10) 2.7% (9) 0.88% (1) 0 3.28% (2) 0
mRNA/protein ↓ 10.62% (53) 9.91% (33) 0 11.93% (21) 0 6.67% (10)
Multiple alteration 1.2% (6) 0.6% (2) 0 0.57% (1) 0 2.67% (4)
Patients_Altered 17% (85) 15% (51) 38% (31) 33% (21) 10% (6) 15% (23)
IP3R1 IP3R2 IP3R3 PP2AA PP2AB PP2AC Mutation 1.8% (9) 2.1% (7) 4.39% (5) 2.84% (5) 8.2% (5) 2% (3)
Amplification 0.8% (4) 0.6% (2) 34.21% (39) 5.11% (9) 4.92% (3) 2% (3)
Deep deletion 11.82% (59) 12.31% (41) 1.75% (2) 2.27% (4) 14.75% (9) 4% (6)
mRNA/protein ↓ 22.44% (112) 20.72% (69) 0 30.68% (54) 0 15.33% (23)
Multiple alteration 8.22% (41) 6.01% (20) 0 7.39% (13) 1.64% (1) 9.33% (14)
Patients_Altered 45% (224) 42% (139) 47% (38) 68% (43) 31% (18) 33% (49)
CaSR Mutation 0.6% (3) 0.6% (2) 0 0 1.64% (1) 2% (3)
Amplification 0.8% (4) 0.6% (2) 17.54% (20) 3.41% (6) 3.28% (2) 0.67% (1)
Deep deletion 0.8% (4) 0.6% (2) 0 0.57% (1) 0 0
mRNA/protein ↓ 2.2% (11) 1.2% (4) 0 3.41% (6) 0 2% (3)
Multiple alteration 0 0 0.88% (1) 0 0 0.67% (1)
Patients_Altered 4% (22) 3% (10) 25% (20) 13% (8) 5% (3) 5% (8)
  1. ↓means downregulation; all data output from prostate cancer studies at http://www.cbioportal.org/index.do